Ganetespib - CAS 888216-25-9
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Hsp90 | HSP
Ganetespib, also known as STA-9090, is a synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor STA-9090 binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional Hsp90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of "client" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors. Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
Ganetespib (STA-9090) is an Hsp90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474.
White solid powder
STA-9090;   STA 9090; STA9090
DMSO > 40 mg/mL
3 years -20oC powder, 6 months-80oC in solvent.
Quality Standard:
Canonical SMILES:
Current Developer:
1.A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
Thakur MK1, Heilbrun LK1, Sheng S1, Stein M2, Liu G3, Antonarakis ES4, Vaishampayan U1, Dzinic SH1, Li X1, Freeman S1, Smith D1, Heath EI5. Invest New Drugs. 2016 Feb;34(1):112-8. doi: 10.1007/s10637-015-0307-6. Epub 2015 Nov 18.
Introduction Heat shock protein 90 (Hsp90) has been studied as a therapeutic target in many cancers. In preclinical trials, the Hsp90 ATPase inhibitor ganetespib demonstrated potent inhibition of solid tumor growth, with superior potency than prior Hsp90 inhibitors. Given the promising preclinical outcome and favorable pharmacologic properties of ganetespib, we conducted a phase II trial of single-agent ganetespib in patients with metastatic, castrate-resistant prostate cancer (mCRPC). The primary objective of the study was to determine the 6-month progression-free survival (PFS) rate. Methods Patients with mCRPC who had been previously treated with docetaxel were enrolled after meeting eligibility criteria. All patients received ganetespib at 200 mg/m(2) on days 1, 8, and 15 of every 28 days (one cycle). Subjects who tolerated therapy were continued on ganetespib until disease progression. Considering that Hsp90 acetylation may confer insensitivity to Hsp90 inhibitors and maspin inhibits protein deacetylation, maspin-associated molecular markers were evaluated.
2.Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP1, Mezina A1, Shaib WL1, Landry J2, El-Rayes BF3. Eur J Cancer. 2016 Jan;52:109-19. doi: 10.1016/j.ejca.2015.10.057. Epub 2015 Dec 9.
BACKGROUND: Pancreatic cancer (PC) is an aggressive malignancy characterised by chemoresistance. HSP90 is important for stabilisation of proteins, cell signalling and malignant growth. We hypothesised that ganetespib, an HSP90 inhibitor, can inhibit PC cell growth by interfering with multiple signalling cascades, including the Janus-activated kinase (JAK)-STAT pathway, and act synergistically with chemotherapeutic drugs.
3.Ganetespib: research and clinical development.
Jhaveri K1, Modi S1. Onco Targets Ther. 2015 Jul 24;8:1849-58. doi: 10.2147/OTT.S65804. eCollection 2015.
Under stressful conditions, the heat shock protein 90 (HSP90) molecular chaperone protects cellular proteins (client proteins) from degradation via the ubiquitin-proteasome pathway. HSP90 expression is upregulated in cancers, and this contributes to the malignant phenotype of increased proliferation and decreased apoptosis and maintenance of metastatic potential via conservation of its client proteins, including human epidermal growth factor receptor 2, anaplastic lymphoma kinase, androgen receptor, estrogen receptor, Akt, Raf-1, cell cycle proteins, and B-cell lymphoma 2 among others. Hence, inhibition of HSP90 leads to the simultaneous degradation of its many clients, thereby disrupting multiple oncogenic signaling cascades. This has sparked tremendous interest in the development of HSP90 inhibitors as an innovative anticancer strategy. Based on the wealth of compelling data from preclinical studies, a number of HSP90 inhibitors have entered into clinical testing.
4.Ganetespib radiosensitization for liver cancer therapy.
Chettiar ST1, Malek R1, Annadanam A1, Nugent KM1, Kato Y2,3, Wang H1, Cades JA1, Taparra K1,4, Belcaid Z5, Ballew M1, Manmiller S1, Proia D6, Lim M3,5, Anders RA7, Herman JM1,3, Tran PT1,3,4,8. Cancer Biol Ther. 2016 Apr 2;17(4):457-66. doi: 10.1080/15384047.2016.1156258.
Therapies for liver cancer particularly those including radiation are still inadequate. Inhibiting the stress response machinery is an appealing anti-cancer and radiosensitizing therapeutic strategy. Heat-shock-protein-90 (HSP90) is a molecular chaperone that is a prominent effector of the stress response machinery and is overexpressed in liver cancer cells. HSP90 client proteins include critical components of pathways implicated in liver cancer cell survival and radioresistance. The effects of a novel non-geldanamycin HSP90 inhibitor, ganetespib, combined with radiation were examined on 3 liver cancer cell lines, Hep3b, HepG2 and HUH7, using in vitro assays for clonogenic survival, apoptosis, cell cycle distribution, γH2AX foci kinetics and client protein expression in pathways important for liver cancer survival and radioresistance. We then evaluated tumor growth delay and effects of the combined ganetespib-radiation treatment on tumor cell proliferation in a HepG2 hind-flank tumor graft model.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Hsp90 Products

CAS 467214-20-6 Alvespimycin

(CAS: 467214-20-6)

Alvespimycin (17-DMAG; KOS-1022; NSC 707545) is a potent, H2O-soluble Hsp90 inhibitor with IC50 of 62 nM.17-DMAG displays ~2 times potency against human Hsp90 t...

CAS 1134156-31-2 VER-155008

(CAS: 1134156-31-2)

VER-155008 is an adenosine-derived inhibitor of heat shock protein 70 (Hsp70; IC50 = 0.5 µM) that is selective over Hsp90.It targets the nucleotide-binding doma...

CAS 888216-25-9 Ganetespib

(CAS: 888216-25-9)

Ganetespib, also known as STA-9090, is a synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhib...

CAS 1428729-56-9 KIN1148

(CAS: 1428729-56-9)

KIN1148, a small-molecule IRF3 agonist, associates with and activates recombinant RIG-I protein in cell-free assays. KIN1148 is a novel influenza vaccine adjuva...

CAS 857402-23-4 Retaspimycin

(CAS: 857402-23-4)

Retaspimycin(IPI 504) is a small-molecule inhibitor of heat shock protein 90 (Hsp90) with antiproliferative and antineoplastic activities.Retaspimycin binds to ...

CAS 940289-57-6 VER-49009

(CAS: 940289-57-6)

VER-49009 is a pyrazole compound inhibitor of Hsp90, IC50 47 nM. It produces a cellular antiproliferative GI50 value of 685 nM when tested against a human cance...

CAS 888216-25-9 Ganetespib

(CAS: 888216-25-9)

Ganetespib, also known as STA-9090, is a synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhib...

(CAS: 218924-25-5)

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.

CAS 70563-58-5 Herbimycin A

Herbimycin A
(CAS: 70563-58-5)

Herbimycin A is an ansamycin antibiotic that acts as a Src family kinase inhibitor. Binds to the SH domain and inhibits the activity of p60v-src and p210BCR-ABL...

CAS 908112-43-6 SNX-2112

(CAS: 908112-43-6)

SNX-2112 is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGF...

(CAS: 100872-83-1)

ML346, a barbituric acid skeleton compound, is a novel activator of Hsp70 which could induce HSF-1-dependent chaperone expression and repair protein folding in ...

EC 144
(CAS: 911397-80-3)

EC 114 is a high affinity, potent and selective Hsp90 inhibitor. IC50 1.1 nM. It exhibits selectivity for Hsp90 over Grp94 and TRAP1 (Ki values are 61 and 255 n...

CAS 908111-22-8 SNX-7081

(CAS: 908111-22-8)

SNX-7081 is a novel small molecule inhibitor of Hsp90. SNX-7081 showed strong binding affinity to Hsp90 and expected induction of Hsp70. NF-kappaB nuclear trans...

CAS 39868-96-7 Chlorobiocin

(CAS: 39868-96-7)

Chlorobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 60μmol/...

CAS 1046859-34-0 PF-04942487

(CAS: 1046859-34-0)

PF-4942847 is a novel oral Hsp90 inhibitor, which is a candidate for clinical development in TNBC by collaboratively targeting multiple signaling pathways. In a...

CAS 303-81-1 Novobiocin

(CAS: 303-81-1)

Novobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the interaction of both p23 and Hsp70 co-chaperones ...

CAS 747412-49-3 Luminespib

(CAS: 747412-49-3)

Luminespib, also known as AUY-922 (or NVP-AUY922), is a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with po...

CAS 2752-65-0 Gambogic acid

Gambogic acid
(CAS: 2752-65-0)

Gambogic acid is a natural product inhibitor of Hsp90.

CAS 912999-49-6 Onalespib

(CAS: 912999-49-6)

Onalespib, also known as AT13387, is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic a...

CAS 934343-74-5 Hsp990

(CAS: 934343-74-5)

Hsp980 is an orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity.  Hsp980 binds to and inhibits the acti...

Chemical Structure

CAS 888216-25-9 Ganetespib

Quick Inquiry

Verification code

Featured Items